PolTREG LLC was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method.
During nearly two years of preparation prior to company’s establishment, business model, commercialization strategy and legal protection of invention were developed together with the University and research team. In July 2015 company was officially established with participation of University’s special purpose vehicle (SPV), R&D team – patent creators and implementation team, experienced in securing external funding and managing innovative projects.
PolTREG LLC is the only entity entitled to implementing the research findings in the area of T-regulatory lymphocytes and using their growth method for clinical use.
Due to positive results of clinical trials of TREG method at the University Clinical Center in Gdansk, sharing this breakthrough therapy with as many patients as possible became the main focus of the company.
In October 2015, Company received a grant from the National Centre for Research and Development under the GO_GLOBAL.pl programme to develop a strategy to enter the US market, through cooperation with the acceleration programme in Silicon Valley.
Also in October 2015, Company received another grant from National Centre for Research and Development. Under the Smart Growth Operational Programme, project “Industrial-scale production of TREGS lymphocytes with the use of bioreactor” will allow the company to conduct studies necesary to expand production capabilities and to increase the efficiency of lymphocyte proliferation.
In November 2015, POLTreg LTD was established as a subsidiary operating in London. Company is responsible for the registration process and attracting investors in order to implement the TREG method in the EU and the USA.
In April 2016, Company’s proposal to Horizon2020 programme has been positively evaluated and awarded a grant. With this new source of funding the company will carry out the analytical work on further steps in the process of registration and commercialization of the method.
PolTREG’s main goal is the implementation of TREG method on the Polish as well as international market. Due to special character of the biotechnology sector (especially red biotechnology, cell therapies) the so called “time-to-market” is much more time-consuming and capital-intensive in comparison to other sectors – requirement for clinical trials, registration processes for safety and well-being of patients.
From the medical viewpoint, the therapy process begins with the patient’s diagnosis with type 1 diabetes. After medical assessment in hospital, patient is qualified for the programme. At this point, sampling of venous blood is conducted, which will further serve to isolate white blood cells, and from them TREG cells (regulatory T lymphocytes), which after multiplication in sterile laboratory conditions, are subsequently administered to the same patient as a TREG vaccine.